Clinical trials have reported ORRs as low as 6%, with a median progression-free survival (PFS) of only around 3 months.2–4 Though durable responses to anti-PD1/PD-L1 therapies have been observed in ultra-rare STS subtypes5,6 and in patients selected based on specific tumor microenvironment (TME) characteristics, such as the presence of tertiary lymphoid structures (TLS), these findings underscore the complexity of effectively utilizing ICB in STS treatment.7 This evidence concerns the gene CD274 and telomere syndrome.